Springer Nature, the German-British journal publisher, announced plans on Thursday to raise €200 million ($221 million) through an initial public offering (IPO) in Frankfurt. This would mark the first major European listing in the second half of 2024.
Springer Nature’s German IPO : IPO Structure and Goals
The company plans to raise €200 million via a capital increase and the sale of existing shares held by British private equity firm BC Partners, one of its owners. Springer Nature’s IPO will take place on the regulated market — prime standard — of the Frankfurt Stock Exchange, with plans to complete the listing by December 2024, subject to market conditions.
Holtzbrinck Publishing Group, which owns 53% of the company, will not sell any of its shares during the IPO, while BC Partners, which holds 47%, will sell part of its stake.
Financial Performance and Dividend Plan
Springer Nature reported revenues of €1.85 billion in 2023, an increase from €1.82 billion in 2022. The company, which specializes in research, health, and education publishing, also plans to pay a €25 million dividend for the year ending December 2024. After its IPO, Springer Nature aims to pay an annual dividend of 50% of its adjusted net income.
Springer Nature’s German IPO : Market Impact and Advisors
The IPO is expected to boost Europe’s capital markets, which have seen fewer listings in 2024. The transaction follows other high-profile flotations such as Swiss skincare firm Galderma’s $2.4 billion IPO and CVC Capital Partners PLC’s €2 billion listing.
